GLP-1 Evidence

Body composition

How much of GLP-1 weight loss is muscle?

Roughly a quarter to a third of the weight lost on these drugs is lean tissue. That sounds alarming and is mostly normal — but "mostly" is doing real work in that sentence.

Updated 4 min read 17 citations Evidence strength 4/5

Small white coated tablets lying beside their foil blister strip
Rünno · Public domain · Wikimedia Commons

What the body-composition data actually says

A 2025 systematic review and meta-analysis pooled body-composition outcomes across GLP-1 agonists and co-agonists and is the best current summary [1]. A focused systematic review of semaglutide and lean mass reached a compatible conclusion [2]. The consistent finding: lean mass falls, it falls roughly in proportion to what is seen in other weight-loss modalities, and fat mass falls considerably more.

The SURMOUNT-1 body-composition substudy is the most detailed single dataset, measuring compartments directly during tirzepatide-induced weight reduction [3]. Earlier work with semaglutide reported the same direction of effect alongside the appetite findings [7], and a tirzepatide study in type 2 diabetes tied reduced energy intake to fat-mass loss specifically [4].

Proportion of loss that is lean mass

Why "25 to 40 percent" is less frightening than it sounds

Lean mass is not the same thing as muscle. It includes body water, glycogen and its associated water, connective tissue, and the mass of organs that shrink somewhat with substantial weight reduction. A meaningful share of early "lean mass" loss on any weight-loss intervention is glycogen and water, which is why the proportion looks worse in short trials than in long ones.

Someone carrying substantial excess weight also carries extra lean tissue to support it — larger heart, larger kidneys, more skeletal muscle simply to move the mass around. Losing some of that as the load decreases is the expected physiological response, not a complication.

The legitimate concern

Here is where the reassurance stops. If you lose 20% of body weight instead of 7%, then even at an identical proportion of lean loss you have lost nearly three times as much lean tissue in absolute terms. For a 60-year-old with borderline muscle mass to begin with, that is a genuinely different situation from the same percentage in a 30-year-old.

The trials were not designed to answer this. They measured body composition, not strength, gait speed, fall risk or fracture. Those are the outcomes that would tell you whether the lean-mass loss matters clinically, and they have largely not been collected. Anyone claiming confidently in either direction is going beyond the evidence.

What we know and what we do not
QuestionEvidenceConfidence
Does lean mass fall?Yes, consistently across trials [1][2][3]High
Is the proportion unusual versus other weight loss?No clear evidence that it is [1]Moderate
Is absolute lean loss larger because total loss is larger?Arithmetically yesHigh
Does it reduce strength or physical function?Largely not measuredVery low
Does resistance training preserve it?Strongly supported in general weight-loss research; not tested properly in GLP-1 trialsModerate, indirect

What to do about it

The interventions are not controversial even if the GLP-1-specific evidence is thin: resistance training two or three times a week, and enough protein to support it. The practical difficulty is that these drugs suppress appetite, which makes hitting a protein target harder precisely when it matters most. Several people find they need to plan protein deliberately rather than rely on hunger to get them there.

This is also where the guidance intersects with liver disease management, where semaglutide now appears in formal recommendations [8] and where preserving functional capacity is part of the clinical picture.

Common questions

Should I take creatine or a protein supplement?
Protein sufficiency matters and is harder to achieve with suppressed appetite, so a supplement is a reasonable practical tool. Neither has been tested specifically in GLP-1 trials.
Will I look "skinny fat"?
Fat mass falls considerably more than lean mass in the trial data [1][3], so body composition typically improves. Appearance complaints usually reflect the speed of loss and skin laxity rather than the fat-to-lean ratio.
Is this worse for older people?
Plausibly, because they start with less muscle reserve and lose it more readily. It has not been established, because the functional outcomes have not been measured.
Does lifting weights actually help while on these drugs?
It is very likely to, based on the general weight-loss literature. It has not been demonstrated in a properly powered GLP-1 trial, which is a real gap.
Ground-floor pharmacy premises on Teltower Damm in Berlin-Zehlendorf, Germany
Singlespeedfahrer · CC0 · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 17 publications cited on this page by study type. 6821meta-analysis (6)randomised trial (8)review (2)other (1)
17 publications, 2017–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Eisa N, Barood O · Diabetes, obesity & metabolism · 2026 · Meta-analysis DOIPubMed 41877354
  2. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis Nong K, Shi Q, Xie X, et al. · BMJ (Clinical research ed.) · 2026 · Meta-analysis DOIPubMed 42419792
  3. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  4. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration Khawaji A, A Jaly A, A Bakri H, et al. · Journal of obesity · 2025 · Meta-analysis DOIPubMed 40746703Full text
  5. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  6. Anti-diabetic drugs and weight loss in patients with type 2 diabetes Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacological research · 2021 · Systematic review DOIPubMed 34302978
  7. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial Kadowaki T, Kiyosue A, Shingaki T, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40031941
  8. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40318682
  9. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Look M, Dunn JP, Kushner RF, et al. · Diabetes, obesity & metabolism · 2025 · Randomised controlled trial DOIPubMed 39996356Full text
  10. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy) Yabe D, Kawamori D, Seino Y, et al. · Diabetes, obesity & metabolism · 2023 · Randomised controlled trial DOIPubMed 36184780Full text
  11. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Heise T, DeVries JH, Urva S, et al. · Diabetes care · 2023 · Randomised controlled trial DOIPubMed 36857477Full text
  12. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  13. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  14. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  15. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance Bansal MB, Patton H, Morgan TR, et al. · Hepatology (Baltimore, Md.) · 2026 · Review DOIPubMed 41201884
  16. Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence Sattar N, García-Pérez LE, Rodríguez A, et al. · Diabetes, obesity & metabolism · 2025 · Review DOIPubMed 40555920Full text
  17. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study Alissou M, Demangeat T, Folope V, et al. · Diabetes, obesity & metabolism · 2026 · Journal article DOIPubMed 41068996Full text